(Q44437786)

3 December 2017

0 references

The neurohormonal paradigm: have we gone too far? (English)

1 reference

3 December 2017

Stephen S Gottlieb

1

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Journal of the American College of Cardiology

3 December 2017

published in

1 reference

3 December 2017

volume

41

1 reference

3 December 2017

issue

9

1 reference

3 December 2017

page(s)

1458-1459

1 reference

Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Prognostic value of plasma endothelin-1 in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Vasopressin antagonists in CHF: ready for clinical trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900195-5

7 January 2021

10.1016/S0735-1097(03)00195-5

Identifiers

DOI

1 reference

release_m6xpsil5zjcczm54qxy5ses4m4

3 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m6xpsil5zjcczm54qxy5ses4m4

24 November 2022

mapped directly with Wikidata item

1 reference